scholarly article | Q13442814 |
P356 | DOI | 10.4088/JCP.12M08093 |
P698 | PubMed publication ID | 23945458 |
P50 | author | Augustus John Rush | Q21104277 |
Maurizio Fava | Q30089873 | ||
Roy H. Perlis | Q88592183 | ||
Cristina Cusin | Q114238404 | ||
P2093 | author name string | Andrew A Nierenberg | |
Dan V Iosifescu | |||
Nadia Iovieno | |||
P433 | issue | 7 | |
P921 | main subject | placebo-controlled trial | Q108853737 |
placebo | Q269829 | ||
P304 | page(s) | e636-41 | |
P577 | publication date | 2013-07-01 | |
P1433 | published in | The Journal of Clinical Psychiatry | Q7743563 |
P1476 | title | A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder | |
P478 | volume | 74 |
Q48073684 | Abnormal behaviours during pramipexole treatment for Cotard's syndrome: a case report. |
Q40567300 | Analysis of pramipexole dose-response relationships in Parkinson's disease |
Q38637621 | Backing into the future: pharmacological approaches to the management of resistant depression |
Q37197216 | Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments |
Q28265851 | Dopamine D3 receptor-preferring agonist enhances the subjective effects of cocaine in humans |
Q57461556 | Dopamine Release in Antidepressant-Naive Major Depressive Disorder: A Multimodal [C]-(+)-PHNO Positron Emission Tomography and Functional Magnetic Resonance Imaging Study |
Q47123548 | Dopamine System Dysregulation in Major Depressive Disorders. |
Q93184949 | Efficacy of low-dose D2/D3 partial agonist pramipexole on neuroleptic-induced extrapyramidal symptoms and symptoms of schizophrenia: a stage-1 open-label pilot study |
Q47305318 | Imaging the role of inflammation in mood and anxiety-related disorders |
Q38915253 | Inflammation Effects on Motivation and Motor Activity: Role of Dopamine |
Q38574699 | Managing inadequate antidepressant response in depressive illness. |
Q36091234 | Pharmacologic approaches to treatment resistant depression: Evidences and personal experience |
Q26783002 | Pharmacological Approaches for Treatment-resistant Bipolar Disorder |
Q26798241 | Pharmacological approaches to the challenge of treatment-resistant depression |
Q37188026 | Pramipexole Impairs Stimulus-Response Learning in Healthy Young Adults |
Q39301010 | Pramipexole augmentation in treatment-resistant major depressive disorder |
Q39417632 | Psychiatric comorbidities in movement disorders. |
Q35580361 | Rodent models of treatment-resistant depression. |
Q35862776 | Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders |
Q92384224 | Sleep therapeutics and neuropsychiatric illness |
Q34550088 | Striatal dopamine D2/3 receptor availability in treatment resistant depression |
Q95643359 | Structural Plasticity Induced by Ketamine in Human Dopaminergic Neurons as Mechanism Relevant for Treatment-Resistant Depression |
Q38181363 | The integrative management of treatment-resistant depression: a comprehensive review and perspectives |
Q38543238 | Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder |
Search more.